Recital 3, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

In forcesince 16 Dec 1999

in the European Union, only limited action has been taken so far, whether at national or at Community level, to stimulate the development of orphan medicinal products; such action is best taken at Community level in order to take advantage of the widest possible market and to avoid the dispersion of limited resources; action at Community level is preferable to uncoordinated measures by the Member States which may result in distortions of competition and barriers to intra-Community trade;